 CAMBRIDGE, Mass., Aug. 03, 2022 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. NASDAQ: MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report financial results for the second quarter ended June 30, 2022 on Monday, August 8, 2022 and will host a conference call and webcast at 4:30 p.m. Eastern Time that afternoon. Members of management will also be presenting at two upcoming conferences. Details are as follows: 